Korean Post-marketing Surveillance for Sprycel®
The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Sprycel® so that the regulatory authority can manage the marketing approval properly.
Leukemia, Myelomonocytic, Chronic|Leukemia-Lymphoma
Adverse events occurrence, 30 days after last dose of study drug
Improvement in hematologic response, The number and percentage of subjects who satisfy each criterion of hematologic responses (Complete/No response) will be presented as frequency distribution. McNemar test will be conducted to test the change from the baseline value, 4 weeks after registration|Improvement in cytogenetic response, The number and percentage of subjects who satisfy each criterion of cytogenetic responses (Complete/Partial/Minor/Minimal/No response) will be presented as frequency distribution. McNemar test will be conducted to test the change from the baseline value, 12 weeks after registration|Overall efficacy assessment by investigator's discretion, Based on demographic factors, treatment factors like medical history and concomitant medication, 4 weeks after registration
The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Sprycel® so that the regulatory authority can manage the marketing approval properly.